Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
February 2022
-
Key Release
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12… -
Key Release
Novartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative… -
Key Release
Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den…
January 2022
-
Statement
2021 Global Managed Access Program Community Update
-
Media Release
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo,… -
Media Release
Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function
Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of… -
Media Release
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a…
December 2021
-
Media Release
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both… -
Key Release
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol… -
Media Release
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2 Acquisition will add GT005 to the Novartis portfolio… -
Media Release
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.Breast cancer is one of most common types of… -
Media Release
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal…